{"abstract":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development, an institute of the National Institutes of Health, United States Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice to EnZeta Immunotherapies, Inc., a company located in Coral Gables, FL.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2025/12/23/2025-23691.html","cfr_references":[],"citation":"90 FR 60111","comment_url":null,"comments_close_on":"2026-01-07","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center, representing the Eunice Kennedy Shriver National Institute of Child Health and Human Development, on or before January 7, 2026 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2025-23691","effective_on":null,"end_page":60112,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2025/12/23/2025-23691.xml","html_url":"https://www.federalregister.gov/documents/2025/12/23/2025-23691/prospective-grant-of-an-exclusive-patent-license-enhanced-tumor-reactivity-of-t-cells-lacking-sit1","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2025-23691?publication_date=2025-12-23","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2025-12-23/2025-23691/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":87,"last_updated":"2026-06-26 16:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-12-23/pdf/2025-23691.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-23691.pdf?1766411115","publication_date":"2025-12-23","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2025/12/23/2025-23691.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2025-12-23T09:07:40Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":60111,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1, or TRAT1","toc_doc":"Enhanced Tumor Reactivity of T Cells Lacking Sit1, Lax1, or Trat1; Exclusive Patent","toc_subject":"Licenses; Exemptions, Applications, Amendments, etc.","topics":[],"type":"Notice","volume":90}